Home > News & Media > News
Communication starts here.
2015.08
TWi Pharmaceuticals Announces 2Q 2015 Financial Results and EPS for 2Q of NT$0.69
2015.08
TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in Europe and Russia
2015.07
TWi Pharmaceuticals Launches Generic MEGACE ES® After Favorable Decision In Patent Suit
2015.06
TWi Pharmaceuticals Receives US FDA Final Approval on Generic Guanfacine HCl ER Tablet
2015.05
TWi Pharmaceuticals Announced the promotion of R&D EVP Jianbo Xie as COO
2015.04
TWi Announces Settlement with Takeda on Dexilant® Litigation
2015.04
TWi Pharmaceuticals USA Announces the Receipt of State Sales Licenses from All 50 States in the U.S.
2015.03
TWi Pharmaceuticals announces the first shipment of its generic product in the U.S. market.
2015.03
TWi Biotechnology Receives Rare Disease Drug Designation for its Drug Candidate AC-203 in Taiwan.
2015.03
TWi Pharmaceuticals announces that its Board has appointed Ms. Tina Guilder as the President & CEO and Ms. Eva Ho as CFO to enhance the strategic move to commercialize its products in the U.S. market.

 

Pages:1 - 2 - 3 - 4 - 5« Pre · Next »